Fibrin degradation product

peptide

Fibrin degradation products indicate active fibrinolytic remodeling and coagulation turnover during acute MI.

Pathway placement

Cascade stepCoagulation & thrombus formation

Confidencehigh

RationaleMarker of fibrin turnover and coagulation-fibrinolytic balance in acute coronary thrombosis.

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)+12.1

Confounder panel (Type-II drivers)

No confounder evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)

Collection tube

K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)

Method / principle

Competitive/sandwich immunoassay or LC-MS/MS

Reagent / substrate

Anti-peptide antibody; or isotope-labeled internal standard (MS)

Platform

Immunoassay / LC-MS/MS

Turnaround · availability

Send-out / research · Research-grade